BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 35268738)

  • 21. 1,2,4 triazolo[1,5-a] pyrimidin-7-ones as novel SARS-CoV-2 Main protease inhibitors: In silico screening and molecular dynamics simulation of potential COVID-19 drug candidates.
    Kavitha K; Sivakumar S; Ramesh B
    Biophys Chem; 2020 Dec; 267():106478. PubMed ID: 33022567
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Novel inhibitors of the main protease enzyme of SARS-CoV-2 identified via molecular dynamics simulation-guided in vitro assay.
    Loschwitz J; Jäckering A; Keutmann M; Olagunju M; Eberle RJ; Coronado MA; Olubiyi OO; Strodel B
    Bioorg Chem; 2021 Jun; 111():104862. PubMed ID: 33862474
    [TBL] [Abstract][Full Text] [Related]  

  • 23. In silico identification of potential inhibitors of key SARS-CoV-2 3CL hydrolase (Mpro) via molecular docking, MMGBSA predictive binding energy calculations, and molecular dynamics simulation.
    Choudhary MI; Shaikh M; Tul-Wahab A; Ur-Rahman A
    PLoS One; 2020; 15(7):e0235030. PubMed ID: 32706783
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Interaction of small molecules with the SARS-CoV-2 papain-like protease: In silico studies and in vitro validation of protease activity inhibition using an enzymatic inhibition assay.
    Pitsillou E; Liang J; Ververis K; Hung A; Karagiannis TC
    J Mol Graph Model; 2021 May; 104():107851. PubMed ID: 33556646
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Phenylbenzopyrone of Flavonoids as a Potential Scaffold to Prevent SARSCoV-2 Replication by Inhibiting its M
    Potshangbam AM; Nongdam P; Kumar AK; Rathore RS
    Curr Pharm Biotechnol; 2021; 22(15):2054-2070. PubMed ID: 33504301
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Structure-activity relationship (SAR) and molecular dynamics study of withaferin-A fragment derivatives as potential therapeutic lead against main protease (M
    Ghosh A; Chakraborty M; Chandra A; Alam MP
    J Mol Model; 2021 Feb; 27(3):97. PubMed ID: 33641023
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Anti-HIV-drug and phyto-flavonoid combination against SARS-CoV-2: a molecular docking-simulation base assessment.
    Swain SS; Singh SR; Sahoo A; Hussain T; Pati S
    J Biomol Struct Dyn; 2022 Sep; 40(14):6463-6476. PubMed ID: 33583350
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Structure-based screening of novel lichen compounds against SARS Coronavirus main protease (Mpro) as potentials inhibitors of COVID-19.
    Joshi T; Sharma P; Joshi T; Pundir H; Mathpal S; Chandra S
    Mol Divers; 2021 Aug; 25(3):1665-1677. PubMed ID: 32602074
    [TBL] [Abstract][Full Text] [Related]  

  • 29. In silico prediction of potential inhibitors for the main protease of SARS-CoV-2 using molecular docking and dynamics simulation based drug-repurposing.
    Kumar Y; Singh H; Patel CN
    J Infect Public Health; 2020 Sep; 13(9):1210-1223. PubMed ID: 32561274
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Computational simulations on the binding and reactivity of a nitrile inhibitor of the SARS-CoV-2 main protease.
    Ramos-Guzmán CA; Ruiz-Pernía JJ; Tuñón I
    Chem Commun (Camb); 2021 Sep; 57(72):9096-9099. PubMed ID: 34498651
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Identification of potential plant-based inhibitor against viral proteases of SARS-CoV-2 through molecular docking, MM-PBSA binding energy calculations and molecular dynamics simulation.
    Gogoi B; Chowdhury P; Goswami N; Gogoi N; Naiya T; Chetia P; Mahanta S; Chetia D; Tanti B; Borah P; Handique PJ
    Mol Divers; 2021 Aug; 25(3):1963-1977. PubMed ID: 33856591
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Evaluation of phytoconstituents of
    Choudhary P; Singh T; Amod A; Singh S
    J Biomol Struct Dyn; 2023 Jun; 41(9):4106-4123. PubMed ID: 35467486
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Marine Brominated Tyrosine Alkaloids as Promising Inhibitors of SARS-CoV-2.
    El-Demerdash A; Hassan A; Abd El-Aziz TM; Stockand JD; Arafa RK
    Molecules; 2021 Oct; 26(20):. PubMed ID: 34684755
    [TBL] [Abstract][Full Text] [Related]  

  • 34. 2-Pyridone natural products as inhibitors of SARS-CoV-2 main protease.
    Forrestall KL; Burley DE; Cash MK; Pottie IR; Darvesh S
    Chem Biol Interact; 2021 Feb; 335():109348. PubMed ID: 33278462
    [TBL] [Abstract][Full Text] [Related]  

  • 35. An efficient eco-friendly, simple, and green synthesis of some new spiro-N-(4-sulfamoyl-phenyl)-1,3,4-thiadiazole-2-carboxamide derivatives as potential inhibitors of SARS-CoV-2 proteases: drug-likeness, pharmacophore, molecular docking, and DFT exploration.
    El-Saghier AM; Enaili SS; Abdou A; Kadry AM
    Mol Divers; 2024 Feb; 28(1):249-270. PubMed ID: 37946070
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Molecular Docking of Azithromycin, Ritonavir, Lopinavir, Oseltamivir, Ivermectin and Heparin Interacting with Coronavirus Disease 2019 Main and Severe Acute Respiratory Syndrome Coronavirus-2 3C-Like Proteases.
    Arouche TDS; Martins AY; Ramalho TC; Júnior RNC; Costa FLP; Filho TSA; Neto AMJC
    J Nanosci Nanotechnol; 2021 Apr; 21(4):2075-2089. PubMed ID: 33500022
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Screening potential FDA-approved inhibitors of the SARS-CoV-2 major protease 3CL
    Liu WS; Li HG; Ding CH; Zhang HX; Wang RR; Li JQ
    Aging (Albany NY); 2021 Mar; 13(5):6258-6272. PubMed ID: 33678621
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Virtual screening, ADMET profiling, PASS prediction, and bioactivity studies of potential inhibitory roles of alkaloids, phytosterols, and flavonoids against COVID-19 main protease (M
    Abdul-Hammed M; Adedotun IO; Olajide M; Irabor CO; Afolabi TI; Gbadebo IO; Rhyman L; Ramasami P
    Nat Prod Res; 2022 Jun; 36(12):3110-3116. PubMed ID: 34107799
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Targeting SARS-CoV-2 Main Protease: A Computational Drug Repurposing Study.
    Baby K; Maity S; Mehta CH; Suresh A; Nayak UY; Nayak Y
    Arch Med Res; 2021 Jan; 52(1):38-47. PubMed ID: 32962867
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Identification of FDA approved drugs against SARS-CoV-2 RNA dependent RNA polymerase (RdRp) and 3-chymotrypsin-like protease (3CLpro), drug repurposing approach.
    Molavi Z; Razi S; Mirmotalebisohi SA; Adibi A; Sameni M; Karami F; Niazi V; Niknam Z; Aliashrafi M; Taheri M; Ghafouri-Fard S; Jeibouei S; Mahdian S; Zali H; Ranjbar MM; Yazdani M
    Biomed Pharmacother; 2021 Jun; 138():111544. PubMed ID: 34311539
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.